The Sapien M3 device is the first approved mitral regurgitation treatment to use a transseptal approach, Edwards said.

Edwards Lifesciences has claimed an FDA approval for its Sapien M3 transcatheter mitral valve replacement system—marking the ...

Edwards Lifesciences announced today that its Sapien M3 mitral valve replacement system received FDA approval for mitral ...

First-of-its-kind Edwards SAPIEN M3 transcatheter mitral valve system secures FDA approval for transseptal mitral ...

Edwards Lifesciences (NYSE: EW) today announced the company’s SAPIEN M3 mitral valve replacement system is the first ...

The US Food and Drug Administration has approved the Sapien M3 system for transseptal transcatheter mitral valve replacement (TMVR) for use in patients with symptomatic moderate-to-severe mitral ...

Edwards Lifesciences (EW) announced its SAPIEN M3 mitral valve replacement system is the first transcatheter therapy utilizing a transseptal ...

Patient will be placed under general anesthesia. An endotracheal tube will be inserted into the patient’s windpipe and connected to a ventilator to assist the patient’s breathing. Another probe will ...

Almost 20 years’ worth of follow-up in an international registry shows that patients with degenerative mitral regurgitation who underwent mitral valve (MV) repair had better survival, fewer ...

Patients who underwent mitral valve replacement had a more than threefold higher 10-year rate of infective endocarditis than those at moderate risk for the disease, whereas undergoing mitral valve ...

Dear Mayo Clinic: Is minimally invasive heart surgery to repair a mitral valve a safer option than open-heart surgery? Is it common for a surgeon to have to switch to an open-heart procedure after ...

Bioprosthetic valves lasts about 10-15 years. These are usually obtained from animals or human organ donors. Tissue valves seem to improve the patient’s hemodynamics, but tend to stiffen in 10-15 ...